Low-dose adjuvant dexmedetomidine did not decrease propofol sedation requirements in children undergoing gastrointestinal endoscopy.
dexmedetomidine
esophagogastroduodenoscopy
pediatric
propofol
sedation
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
01
09
2022
received:
08
06
2022
accepted:
05
09
2022
pubmed:
16
9
2022
medline:
19
10
2022
entrez:
15
9
2022
Statut:
ppublish
Résumé
Propofol is the cornerstone of deep sedation during pediatric esophagogastroduodenoscopy (EGD), though adjuvant dexmedetomidine may provide propofol-sparing benefits. The objective of the study was to evaluate whether adjuvant dexmedetomidine decreases the total propofol dose in pediatric patients undergoing EGD. This single-center, retrospective, cohort study evaluated the total propofol dose in pediatric patients undergoing EGD with and without the use of adjuvant dexmedetomidine. Secondary outcomes included the change in hemodynamics across the perioperative continuum and post-procedure recovery time. A multivariable general linear regression was performed to identify associated variables for recovery time post-procedure. A total of 159 patients were included in the study; 88 patients received dexmedetomidine and propofol (DEX-PRO), and 71 patients received propofol only (PRO). The median [interquartile range (IQR)] propofol dose in the DEX-PRO group was 0.26 [IQR, 0.17-0.36] mg kg Adjuvant dexmedetomidine did not reduce propofol requirements compared with propofol alone in pediatric patients undergoing EGD. More hypotension and a longer postoperative recovery time were also seen in patients receiving adjuvant dexmedetomidine for their endoscopic procedure.
Sections du résumé
BACKGROUND
Propofol is the cornerstone of deep sedation during pediatric esophagogastroduodenoscopy (EGD), though adjuvant dexmedetomidine may provide propofol-sparing benefits.
OBJECTIVE
The objective of the study was to evaluate whether adjuvant dexmedetomidine decreases the total propofol dose in pediatric patients undergoing EGD.
METHODS
This single-center, retrospective, cohort study evaluated the total propofol dose in pediatric patients undergoing EGD with and without the use of adjuvant dexmedetomidine. Secondary outcomes included the change in hemodynamics across the perioperative continuum and post-procedure recovery time. A multivariable general linear regression was performed to identify associated variables for recovery time post-procedure.
RESULTS
A total of 159 patients were included in the study; 88 patients received dexmedetomidine and propofol (DEX-PRO), and 71 patients received propofol only (PRO). The median [interquartile range (IQR)] propofol dose in the DEX-PRO group was 0.26 [IQR, 0.17-0.36] mg kg
CONCLUSION
Adjuvant dexmedetomidine did not reduce propofol requirements compared with propofol alone in pediatric patients undergoing EGD. More hypotension and a longer postoperative recovery time were also seen in patients receiving adjuvant dexmedetomidine for their endoscopic procedure.
Substances chimiques
Hypnotics and Sedatives
0
Dexmedetomidine
67VB76HONO
Propofol
YI7VU623SF
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
792-797Subventions
Organisme : NIH National Center for Advancing Translational Sciences
ID : UL1TR001998
Informations de copyright
© 2022 Pharmacotherapy Publications, Inc.
Références
Oh SH. Sedation in pediatric esophagogastroduodenoscopy. Clin Endosc. 2018;51(2):120-128. doi:10.5946/ce.2018.028
van Beek EJ, Leroy PL. Safe and effective procedural sedation for gastrointestinal endoscopy in children. J Pediatr Gastroenterol Nutr. 2012;54:171-185.
Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol for procedural sedation in children in the emergency department. Ann Emerg Med. 2003;42:773-782.
Morgan DJ, Campbell GA, Crankshaw DP. Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmac. 1990;30:144-148.
Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH, Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the pediatric sedation research consortium. Anesth Analg. 2009;108:795-804.
Kamat PP, McCracken CE, Gillespie SE, et al. Pediatric critical care physician-administered procedural sedation using propofol: a report from the pediatric sedation research consortium database. Pediatr Crit Care Med. 2015;16(1):11-20.
Roback MG, Carlson DW, Babl FE, Kennedy RM. Update on pharmacological management of procedural sedation for children. Curr Opin Anaesthesiol. 2016;29(Suppl 1):S21-S35. doi:10.1097/ACO.0000000000000316
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263-306.
Le Guen M, Liu N, Tounou F, et al. Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anesthesia: a double-blind, placebo-controlled trial. Anesth Analg. 2014;118(5):946-955.
Dutta A, Sethi N, Sood J, et al. The effect of dexmedetomidine on propofol requirements during anesthesia administered by Bispectral index-guided closed-loop anesthesia delivery system: a randomized controlled study. Anesth Analg. 2019;129(1):84-91.
Hammer GB, Sam WJ, Chen MI, Golianu B, Drover DR. Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. Paediatr Anaesth. 2009;19(2):138-144.
Nagoshi M, Reddy S, Bell M, et al. Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: a double-cohort study. Paediatr Anaesth. 2018;28(7):639-646. doi:10.1111/pan.13400
Moncel JB, Nardi N, Wodey E, Pouvreau A, Ecoffey C. Evaluation of the pediatric post anesthesia discharge scoring system in an ambulatory surgery unit. Paediatr Anaesth. 2015;25(6):636-641. doi:10.1111/pan.12612
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
Mason KP, Park RS, Sullivan CA, et al. The synergistic effect of dexmedetomidine on propofol for paediatric deep sedation: a randomised trial. Eur J Anaesthesiol. 2021;38(5):541-547. doi:10.1097/EJA.0000000000001350
West N, Görges M, Poznikoff A, Whyte S, Malherbe S. Association of dexmedetomidine with recovery room and hospital discharge times: a retrospective cohort analysis. Paediatr Anaesth. 2021;31(11):1170-1178. doi:10.1111/pan.14257
Wu J, Mahmoud M, Schmitt M, Hossain M, Kurth D. Comparison of propofol and dexmedetomedine techniques in children undergoing magnetic resonance imaging. Paediatr Anaesth. 2014;24(8):813-818. doi:10.1111/pan.12408